vs
GE医疗（DHC）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
GE医疗的季度营收约是REPLIGEN CORP的1.9倍（$379.6M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs -5.6%，领先12.3%），REPLIGEN CORP同比增速更快（13.6% vs -0.0%），REPLIGEN CORP自由现金流更多（$17.6M vs $-166.4M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 1.2%）
GE医疗是一家总部位于美国伊利诺伊州芝加哥市的医疗科技企业，业务涵盖四大板块：医疗影像设备，包括分子成像、CT、核磁共振、妇科健康筛查及X光系统；超声设备；患者护理解决方案，聚焦远程患者监测、麻醉呼吸护理、心脏诊断及婴幼儿护理；此外还涉及医药相关领域，是全球医疗行业的知名企业。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
DHC vs RGEN — 直观对比
营收规模更大
DHC
是对方的1.9倍
$197.9M
营收增速更快
RGEN
高出13.7%
-0.0%
净利率更高
RGEN
高出12.3%
-5.6%
自由现金流更多
RGEN
多$184.0M
$-166.4M
两年增速更快
RGEN
近两年复合增速
1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $379.6M | $197.9M |
| 净利润 | $-21.2M | $13.3M |
| 毛利率 | — | 52.5% |
| 营业利润率 | -12.6% | 9.0% |
| 净利率 | -5.6% | 6.7% |
| 营收同比 | -0.0% | 13.6% |
| 净利润同比 | 75.7% | 143.9% |
| 每股收益（稀释后） | $-0.09 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DHCRGEN
| Q4 25 | $379.6M | $197.9M | ||
| Q3 25 | $388.7M | $188.8M | ||
| Q2 25 | $382.7M | $182.4M | ||
| Q1 25 | $386.9M | $169.2M | ||
| Q4 24 | $379.6M | $174.1M | ||
| Q3 24 | $373.6M | $154.9M | ||
| Q2 24 | $371.4M | $154.1M | ||
| Q1 24 | $370.8M | $151.3M |
净利润DHCRGEN
| Q4 25 | $-21.2M | $13.3M | ||
| Q3 25 | $-164.0M | $14.9M | ||
| Q2 25 | $-91.6M | $14.9M | ||
| Q1 25 | $-9.0M | $5.8M | ||
| Q4 24 | $-87.4M | $-30.3M | ||
| Q3 24 | $-98.7M | $-654.0K | ||
| Q2 24 | $-97.9M | $3.3M | ||
| Q1 24 | $-86.3M | $2.1M |
毛利率DHCRGEN
| Q4 25 | — | 52.5% | ||
| Q3 25 | — | 53.2% | ||
| Q2 25 | — | 50.0% | ||
| Q1 25 | — | 53.6% | ||
| Q4 24 | — | 26.1% | ||
| Q3 24 | — | 50.0% | ||
| Q2 24 | — | 49.8% | ||
| Q1 24 | — | 49.5% |
营业利润率DHCRGEN
| Q4 25 | -12.6% | 9.0% | ||
| Q3 25 | -43.4% | 8.9% | ||
| Q2 25 | -24.5% | 7.6% | ||
| Q1 25 | -2.7% | 3.9% | ||
| Q4 24 | -26.1% | -17.7% | ||
| Q3 24 | -26.5% | -5.1% | ||
| Q2 24 | -23.0% | 1.0% | ||
| Q1 24 | -23.7% | 1.3% |
净利率DHCRGEN
| Q4 25 | -5.6% | 6.7% | ||
| Q3 25 | -42.2% | 7.9% | ||
| Q2 25 | -23.9% | 8.2% | ||
| Q1 25 | -2.3% | 3.4% | ||
| Q4 24 | -23.0% | -17.4% | ||
| Q3 24 | -26.4% | -0.4% | ||
| Q2 24 | -26.3% | 2.2% | ||
| Q1 24 | -23.3% | 1.4% |
每股收益（稀释后）DHCRGEN
| Q4 25 | $-0.09 | $0.24 | ||
| Q3 25 | $-0.68 | $0.26 | ||
| Q2 25 | $-0.38 | $0.26 | ||
| Q1 25 | $-0.04 | $0.10 | ||
| Q4 24 | $-0.37 | $-0.55 | ||
| Q3 24 | $-0.41 | $-0.01 | ||
| Q2 24 | $-0.41 | $0.06 | ||
| Q1 24 | $-0.36 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $105.4M | $767.6M |
| 总债务越低越好 | $2.4B | $542.2M |
| 股东权益账面价值 | $1.7B | $2.1B |
| 总资产 | $4.4B | $2.9B |
| 负债/权益比越低杠杆越低 | 1.47× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资DHCRGEN
| Q4 25 | $105.4M | $767.6M | ||
| Q3 25 | $201.4M | $748.7M | ||
| Q2 25 | $141.8M | $708.9M | ||
| Q1 25 | $302.6M | $697.2M | ||
| Q4 24 | $144.6M | $757.4M | ||
| Q3 24 | $256.5M | $784.0M | ||
| Q2 24 | $265.6M | $809.1M | ||
| Q1 24 | $207.1M | $780.6M |
总债务DHCRGEN
| Q4 25 | $2.4B | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $3.1B | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益DHCRGEN
| Q4 25 | $1.7B | $2.1B | ||
| Q3 25 | $1.7B | $2.1B | ||
| Q2 25 | $1.9B | $2.1B | ||
| Q1 25 | $1.9B | $2.0B | ||
| Q4 24 | $2.0B | $2.0B | ||
| Q3 24 | $2.0B | $2.0B | ||
| Q2 24 | $2.1B | $2.0B | ||
| Q1 24 | $2.2B | $2.0B |
总资产DHCRGEN
| Q4 25 | $4.4B | $2.9B | ||
| Q3 25 | $4.7B | $2.9B | ||
| Q2 25 | $4.8B | $2.9B | ||
| Q1 25 | $5.0B | $2.9B | ||
| Q4 24 | $5.1B | $2.8B | ||
| Q3 24 | $5.3B | $2.8B | ||
| Q2 24 | $5.3B | $2.9B | ||
| Q1 24 | $5.3B | $2.8B |
负债/权益比DHCRGEN
| Q4 25 | 1.47× | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.56× | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-19.6M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $-166.4M | $17.6M |
| 自由现金流率自由现金流/营收 | -43.8% | 8.9% |
| 资本支出强度资本支出/营收 | 38.7% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $-280.3M | $93.9M |
8季度趋势，按日历期对齐
经营现金流DHCRGEN
| Q4 25 | $-19.6M | $25.7M | ||
| Q3 25 | $-49.3M | $48.1M | ||
| Q2 25 | $53.0M | $28.6M | ||
| Q1 25 | $-3.2M | $15.0M | ||
| Q4 24 | $112.2M | $39.2M | ||
| Q3 24 | $21.1M | $49.3M | ||
| Q2 24 | $44.3M | $42.2M | ||
| Q1 24 | $28.6M | $44.7M |
自由现金流DHCRGEN
| Q4 25 | $-166.4M | $17.6M | ||
| Q3 25 | $-89.8M | $43.4M | ||
| Q2 25 | $18.8M | $21.5M | ||
| Q1 25 | $-42.9M | $11.4M | ||
| Q4 24 | $-89.5M | $33.6M | ||
| Q3 24 | $-26.1M | $42.3M | ||
| Q2 24 | $3.3M | $37.4M | ||
| Q1 24 | $-18.1M | $36.4M |
自由现金流率DHCRGEN
| Q4 25 | -43.8% | 8.9% | ||
| Q3 25 | -23.1% | 23.0% | ||
| Q2 25 | 4.9% | 11.8% | ||
| Q1 25 | -11.1% | 6.8% | ||
| Q4 24 | -23.6% | 19.3% | ||
| Q3 24 | -7.0% | 27.3% | ||
| Q2 24 | 0.9% | 24.3% | ||
| Q1 24 | -4.9% | 24.0% |
资本支出强度DHCRGEN
| Q4 25 | 38.7% | 4.1% | ||
| Q3 25 | 10.4% | 2.5% | ||
| Q2 25 | 8.9% | 3.9% | ||
| Q1 25 | 10.2% | 2.1% | ||
| Q4 24 | 53.1% | 3.2% | ||
| Q3 24 | 12.6% | 4.5% | ||
| Q2 24 | 11.0% | 3.1% | ||
| Q1 24 | 12.6% | 5.5% |
现金转化率DHCRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.57× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 12.70× | ||
| Q1 24 | — | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DHC
| Senior Housing Operating Portfolio Segment | $323.4M | 85% |
| Rental Income | $56.2M | 15% |
RGEN
暂无分部数据
